Septal Occluder Device

DEVICE2 trials

Sponsors

W.L.Gore & Associates, IRCCS Ospedale San Raffaele

Conditions

Atrial Fibrillation New OnsetPatent Foramen OvaleStrokeStroke, CryptogenicTransient Ischaemic Attack Due to EmbolismTransient Ischemic Attack

Unknown Phase

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

CompletedNCT00738894

W.L.Gore & AssociatesStroke, Transient Ischemic Attack

Start: 2008-12-10End: 2020-05-11Updated: 2020-11-20

PFO tRanscatether Occlusion Long-term Outcomes National Group (PROLONG) Registry

CompletedNCT06504121

IRCCS Ospedale San RaffaeleAtrial Fibrillation New Onset, Patent Foramen Ovale, Stroke, Cryptogenic +1

Start: 1999-01-31End: 2024-06-30Updated: 2024-07-16

Related Papers

15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism

JACC: Cardiovascular Interventions2025-06-012 citations

Patent Foramen Ovale Closure Decreases the Incidence but Not the Size of New Brain Infarction on Magnetic Resonance Imaging: An Analysis of the REDUCE Trial

Stroke2021-08-306 citations

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

New England Journal of Medicine2017-09-131078 citations

Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study

International Journal of Stroke2017-03-2413 citations